JP2009525829A - 単針生体内エレクトロポレーションのための装置および方法 - Google Patents
単針生体内エレクトロポレーションのための装置および方法 Download PDFInfo
- Publication number
- JP2009525829A JP2009525829A JP2008554405A JP2008554405A JP2009525829A JP 2009525829 A JP2009525829 A JP 2009525829A JP 2008554405 A JP2008554405 A JP 2008554405A JP 2008554405 A JP2008554405 A JP 2008554405A JP 2009525829 A JP2009525829 A JP 2009525829A
- Authority
- JP
- Japan
- Prior art keywords
- needle
- tissue
- cells
- electrode
- gauge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000001727 in vivo Methods 0.000 title claims abstract description 6
- 238000004520 electroporation Methods 0.000 title claims description 80
- 210000001519 tissue Anatomy 0.000 claims abstract description 117
- 230000005684 electric field Effects 0.000 claims abstract description 46
- 230000002441 reversible effect Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 79
- 238000002347 injection Methods 0.000 claims description 49
- 239000007924 injection Substances 0.000 claims description 49
- 239000000463 material Substances 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 22
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 12
- 239000010931 gold Substances 0.000 claims description 12
- 229910052737 gold Inorganic materials 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 230000000149 penetrating effect Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 210000002027 skeletal muscle Anatomy 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 210000003699 striated muscle Anatomy 0.000 claims description 4
- -1 BCGF Proteins 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000003815 Interleukin-11 Human genes 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 108010002335 Interleukin-9 Proteins 0.000 claims description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 210000002948 striated muscle cell Anatomy 0.000 claims 1
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 38
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 38
- 239000005090 green fluorescent protein Substances 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 239000012530 fluid Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 238000013461 design Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000052 poly(p-xylylene) Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000005459 micromachining Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- HTXDPTMKBJXEOW-UHFFFAOYSA-N dioxoiridium Chemical compound O=[Ir]=O HTXDPTMKBJXEOW-UHFFFAOYSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910000457 iridium oxide Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Electrotherapy Devices (AREA)
- Finger-Pressure Massage (AREA)
Abstract
Description
ICAMからなるグループから選択した免疫変調分子といった活性分子を含む免疫関連生物活性分子を備えてもよい。
以下の例は、本発明によってなされた様々な実施形態を例示するために与えられる。以下の例は本発明によって用意可能な多くの種類の実施形態を包括または網羅するものではないことを理解されたい。
ここで本発明の様々な態様を参照すると、装置は、例えば(図5)に示すように、分子送達槽20および電極針10という構成要素を備えてもよい。追加実施形態は、シャープスカバー11、(シリンジ針の貫通によるなどして)槽を充填する際使用する槽20を備える構造の一部を封止する弾性隔膜12と、シャープスカバー11を開/後退(図5C)または閉/被覆(図5Aおよび図5B)の何れかの半固定位置に保持するための槽20の収容構造内のディンプル13ならびにくぼみ14および14*といった機構とを含む。さらなる実施形態は、例えばディンプル15ならびにくぼみ16および16*といった、プランジャ9を半固定の開/後退または閉/排出位置に保持するための機構を含む。シャープスカバー11およびプランジャ9の半固定位置決めを提供するために利用される方法に関わらず、こうした位置は、手の力といった作動エネルギー、または電動アクチュエータといった機械的エネルギーの何れかによって容易に変更してよいことは当業者に明らかであろう。シャープスカバー11の末端は着脱式に取り付けられた無菌カバー60を含んでもよい。電極針10はさらに、内部を通り、組織穿刺先端22と、槽20に接続するオリフィス25とを端部とする内腔を備えてもよい(図1参照)。注射針10は標準皮下注射針ゲージサイズが18〜29ゲージのものでよい。好適実施形態では、送達針は図1の電極21aおよび21bのような少なくとも1対の電極を備える。電極は、電極リード線24aおよび24bと電気的に連絡する少なくとも1つの陽極と1つの陰極とを備える。本発明の何らかの特定の製品のために選択された設計に応じて、リード線はリード端子23を終端としてもよく(例えば、図3および図4参照)、また何らかの手段によって、電極からパルス発生器のような電気エネルギーの発生源に至るリード線に接続してもよい。針構成要素10はさらに、針構成要素10を皮下注射シリンジポートに脱着式に固定する固定機構によって皮下注射シリンジ槽、またはシリンジ槽に取り付けるためのコネクタ26(図3および図4)を含んでもよい。
この例では、本発明の単針皮下注射針電極を組織に挿入することによって形成された進路沿いおよびその近くに位置する細胞の可逆性のポレーションによる分子の送達についての結果を示す。
この例は、本発明の実施形態に係るエレクトロポレーション装置を利用して、緑色蛍光タンパク質’GFP)を符号化するDNAをウサギの大腿四頭筋に送達する実験を記述するものであって、その結果を図12に示す。
図15および図16にデータを示すこの例では、本発明の電極構成を使用して、SEAP(pSEAP#3348、アルデヴロン社)およびIgG(pLNOH 2hg3 #11765、アルデヴロン社)を符号化するプラスミドを実験動物組織にエレクトロポレーション(すなわち、動物の前脛骨筋への筋内注射)し、発現を監視して、ウサギの筋肉における発現の成功を証明すると共に、「弱」および「強」両方(それぞれSEAPおよびIgG)の抗原に対する免疫反応を測定した。こうした実験ではSEAPおよびIgGプラスミドは1μg/μlの最終濃度で投与した。
この実験では、試作品のMEMで製造した単針電極を、様々なパルスエネルギーと緑色蛍光タンパク質発現を使用してウサギの組織で試験した。表IIに示すように、(1)MEM技術によって、各針の周囲の1/16に、針の全長にわたって陽極と陰極を23ゲージの針に適用した単針電極(図13D〜図13E)、(2)電極が各針軸の周囲の1/4である単針電極(図13A〜図13C)、および(3)流体媒体送達チューブのない、電極が1mm間隔の単針配置、という3つの異なる電極実施形態を試験した。表IIに示すように、パルスの様々な組み合わせを実行した。
Claims (34)
- 組織の細胞内に処置物質を送達するため生体内の前記組織をエレクトロポレーションする装置であって、
a.互いに間隔を開け電気的に絶縁され互いに平行に位置する、チューブの外面に露出した少なくとも2つの細長い電極を備え、体組織に穿通することができる細長い送達チューブと、
b.前記電極を各々電気エネルギー源に接続することができる電気コンジットとを備え、
c.前記チューブを患者の組織に挿入し前記エネルギー源によって通電する時、前記電極が、細胞による前記物質の取り込みを可能にするように前記組織への前記チューブの挿入によって形成された進路に沿ったその近くの細胞を可逆的にポレーションするのに十分な前記チューブを取り囲む処置範囲内の前記細胞に電界を発生することができることを特徴とする装置。 - さらに伸長式または後退式の槽を備える、請求項1に記載の装置。
- 前記槽がシリンジを備える、請求項2に記載の装置。
- 前記槽が、0.0〜0.5ml、0.0〜1ml、0.0〜3ml、および0.0〜5mlからなるグループから選択される可変容量を有する、請求項3に記載の装置。
- 前記電気エネルギー発生源がエレクトロポレーションパルス発生器である、請求項1に記載の装置。
- 前記発生器が、平均電圧が1〜200Vの範囲内でもよい電気パルスを発生することができる、請求項6に記載の装置。
- 前記発生器が、1ミリアンペア〜400ミリアンペアの電流を有する電気パルスを発生することができる、請求項5に記載の装置。
- 前記電流が、10〜40、25〜100、50〜150、125〜200、175〜250、225〜300、250〜300、および300〜400からなるグループから選択される範囲内である、請求項8に記載の装置。
- 前記発生器が、1〜10,000Hzからなるグループから選択される周波数を有する電気パルスを生成することができる、請求項6に記載の装置。
- 前記発生器が、0.1μs〜1000msからなるグループから選択される時間の長さを有する電気パルスを生成することができる、請求項6に記載の装置。
- 前記チューブが、20ゲージ、21ゲージ、22ゲージ、23ゲージ、24ゲージ、25ゲージ、26ゲージ、27ゲージ、28ゲージ、および29ゲージからなるグループから選択される注射針ゲージのサイズの皮下注射針である、請求項1に記載の装置。
- 前記チューブが各電極から電気的に絶縁されている、請求項1に記載の装置。
- 前記組織が、皮膚、皮下組織、皮内組織、真皮下組織、骨格筋、横紋筋、平滑筋、器官、心臓、胸部、肺、膵臓、肝臓、脾臓および粘膜からなるグループから選択される何らかの種類の体組織または器官を備える、請求項1に記載の装置。
- 組織の細胞内に処置物質を送達する装置であって、
近端と末端とを有する細長い軸を各々備え、前記近端で1mmを越えない距離で互いに永続的な関係に固定された、体組織に穿通することができる少なくとも2つの平行な細長い電極を備え、前記装置がさらに、前記電極の長さにわたる各電極に接触する電気的に不活性な材料、および前記電極の長さにわたる前記電極の間の電気的に不活性でない材料からなるグループから選択される構成要素を有する装置。 - 治療上有用な成分によって生体内で細胞をエレクトロポレーションする方法であって、
a.チューブの少なくとも一部に沿って配置された少なくとも2つの細長い電極を備える、前記成分を注射するための前記チューブを提供するステップと、
b.前記成分を収容する槽を提供するステップであって、前記槽と成分とが前記チューブを通る内腔と流通するステップと、
c.前記チューブを患者の生体内の組織に挿入することによって前記患者の事前に選択された処置部位にチャネルを形成するステップと、
d.前記槽から前記内腔を通じて前記チャネルを備える前記処置部位に前記成分を注射するステップと、
e.各前記電極に、前記処置部位に細胞の可逆性のポレーションを発生させるのに十分な電気エネルギーの発生源を提供するステップと、
f.前記電気エネルギーの発生源を起動して、電気パルスを提供し、前記成分を取り込ませるために前記細胞をエレクトロポレーションするステップとを備える方法。 - 前記成分が、薬剤、核酸、抗原、発現可能な抗原を符号化する核酸、発現可能な免疫変調分子を符号化する核酸の何れかを備える、請求項16に記載の方法。
- 前記免疫変調分子がザイトカインまたはケモカインである、請求項17に記載の方法。
- 前記免疫変調分子が、IL−1、IL−2、IL−3、IL−4、IL−5、IL−6、IL−7、IL−8、IL−9、IL−10、IL−11、IL−12、GM−CSF、M−CSF、G−CSF、LIF、LT、TGF−β、IFN、TNF−α、BCGF、CD2、またはICAMからなるグループから選択される、請求項18に記載の方法。
- 前記細胞が、皮下細胞、皮内、真皮下細胞、骨格筋細胞、横紋筋細胞、平滑筋細胞、器官細胞、胸部組織細胞、膵臓細胞、脾臓細胞、心臓細胞、肝細胞および粘膜細胞からなるグループから選択される生きた患者の細胞を備える、請求項16に記載の方法。
- 前記電極が金および/またはチタンを備える、請求項16に記載の方法。
- 前記処置部位が、患者の大腿部、腕、または胴に位置する、請求項16に記載の方法。
- 前記成分が、0.01μl、50μl、100μl、150μl、200μl、250μl、300μl、400μl、および500μlからなるグループから選択される合計量だけ注射される、請求項16に記載の方法。
- 前記成分が、2ng/ml〜3mg/mlからなるグループから選択される合計活性成分濃度で注射される、請求項16に記載の方法。
- 前記成分が、前記細胞を可逆的にポレーションするのに十分な前記エネルギー源を起動する前またはそれと同時に注射される、請求項16に記載の方法。
- 注射後の前記成分が、前記組織への前記チューブの挿入によって形成された前記チャネルの内部および周囲に存在する、請求項24に記載の方法。
- 前記成分が前記処置部位の前記細胞にエレクトロポレーションされる、請求項16に記載の方法。
- 前記処置部位が、前記針によって形成され、1mm、2mm、3mm、4mmおよび5mmからなるグループから選択される距離だけ前記組織内の進路から半径方向外側に延びる、前記進路を取り囲む組織/細胞の範囲を備える、請求項22に記載の方法。
- 前記電気エネルギー発生源がエレクトロポレーションパルス発生器である、請求項1に記載の装置。
- 前記発生器が、公称電圧が1〜200Vとなるようなパルスを発生する、請求項16に記載の方法。
- 前記発生器が、1〜400ミリアンペアからなるグループから選択される定電流でパルスを発生する、請求項13に記載の方法。
- 前記定電流の範囲が、10〜40、25〜100、50〜150、125〜200、175〜250、225〜300、250〜300、および300〜400からなるグループから選択される、請求項13に記載の方法。
- 前記発生器が、1〜10,000Hzの範囲内から選択される周波数でパルスを発生する、請求項16に記載の方法。
- 前記発生器が、約0.1μs〜1000msの時間の長さだけパルスを発生する、請求項13に記載の方法。
- 前記チューブが、20ゲージ、21ゲージ、22ゲージ、23ゲージ、24ゲージ、25ゲージ、26ゲージ、27ゲージ、28ゲージ、および29ゲージからなるグループから選択される注射針ゲージのサイズである、請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77225506P | 2006-02-11 | 2006-02-11 | |
US60/772,255 | 2006-02-11 | ||
PCT/US2007/003615 WO2007095140A2 (en) | 2006-02-11 | 2007-02-09 | Device and method for single-needle in vivo electroporation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009525829A true JP2009525829A (ja) | 2009-07-16 |
JP2009525829A5 JP2009525829A5 (ja) | 2010-03-18 |
JP5059786B2 JP5059786B2 (ja) | 2012-10-31 |
Family
ID=38372038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008554405A Active JP5059786B2 (ja) | 2006-02-11 | 2007-02-09 | 単針生体内エレクトロポレーションのための装置および方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US10369359B2 (ja) |
EP (1) | EP1981581B1 (ja) |
JP (1) | JP5059786B2 (ja) |
KR (1) | KR101385865B1 (ja) |
CN (1) | CN101370553B (ja) |
AU (1) | AU2007215263B2 (ja) |
CA (2) | CA3063263C (ja) |
EA (1) | EA200870252A1 (ja) |
NO (1) | NO340500B1 (ja) |
WO (1) | WO2007095140A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018518314A (ja) * | 2015-06-25 | 2018-07-12 | ニューサウス・イノベーションズ・ピーティーワイ・リミテッド | 治療学的物質の局所的送達を制御する電気穿孔法システム |
JP2018198865A (ja) * | 2017-05-29 | 2018-12-20 | 株式会社ジェイメック | パルス電圧治療装置 |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117651A2 (en) * | 2006-04-07 | 2007-10-18 | University Of South Florida | Passive electric field focus system for in vivo and in vitro applications |
AU2007322075B2 (en) | 2006-11-17 | 2013-07-25 | Genetronics, Inc. | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
EP2280741A4 (en) | 2008-04-29 | 2012-06-13 | Virginia Tech Intell Prop | IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US8926606B2 (en) | 2009-04-09 | 2015-01-06 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
DK2251453T3 (da) | 2009-05-13 | 2014-07-07 | Sio2 Medical Products Inc | Beholderholder |
WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
WO2010148440A1 (en) | 2009-06-24 | 2010-12-29 | International Scientific Pty Ltd | An apparatus and method of treatment utilizing a varying electromagnetic energisation profile |
US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
US20110202052A1 (en) * | 2010-02-12 | 2011-08-18 | Daniel Gelbart | System for treating benign prostatic hyperplasia |
ES2594498T3 (es) | 2010-03-01 | 2016-12-20 | Inovio Pharmaceuticals, Inc. | Un dispositivo de electroporación cutánea tolerable y mínimamente invasivo |
US11624115B2 (en) | 2010-05-12 | 2023-04-11 | Sio2 Medical Products, Inc. | Syringe with PECVD lubrication |
EP2627274B1 (en) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System for electrically ablating tissue of a patient |
US9878101B2 (en) | 2010-11-12 | 2018-01-30 | Sio2 Medical Products, Inc. | Cyclic olefin polymer vessels and vessel coating methods |
WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9272095B2 (en) | 2011-04-01 | 2016-03-01 | Sio2 Medical Products, Inc. | Vessels, contact surfaces, and coating and inspection apparatus and methods |
CN103717249B (zh) | 2011-06-15 | 2017-03-22 | 克洛恩泰克制药股份公司 | 注射针和装置 |
US9913978B2 (en) * | 2011-06-28 | 2018-03-13 | Kate Broderick | Miniminally invasive dermal electroporation device |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US11116695B2 (en) | 2011-11-11 | 2021-09-14 | Sio2 Medical Products, Inc. | Blood sample collection tube |
WO2013071138A1 (en) | 2011-11-11 | 2013-05-16 | Sio2 Medical Products, Inc. | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS |
US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
CA2887352A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
CN104854257B (zh) | 2012-11-01 | 2018-04-13 | Sio2医药产品公司 | 涂层检查方法 |
EP2920567B1 (en) | 2012-11-16 | 2020-08-19 | SiO2 Medical Products, Inc. | Method and apparatus for detecting rapid barrier coating integrity characteristics |
US9764093B2 (en) | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
WO2014085348A2 (en) | 2012-11-30 | 2014-06-05 | Sio2 Medical Products, Inc. | Controlling the uniformity of pecvd deposition on medical syringes, cartridges, and the like |
US9662450B2 (en) | 2013-03-01 | 2017-05-30 | Sio2 Medical Products, Inc. | Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
US9937099B2 (en) | 2013-03-11 | 2018-04-10 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
CA2904611C (en) | 2013-03-11 | 2021-11-23 | Sio2 Medical Products, Inc. | Coated packaging |
WO2014144926A1 (en) | 2013-03-15 | 2014-09-18 | Sio2 Medical Products, Inc. | Coating method |
EP3122917B1 (en) | 2014-03-28 | 2020-05-06 | SiO2 Medical Products, Inc. | Antistatic coatings for plastic vessels |
CN112807074A (zh) | 2014-05-12 | 2021-05-18 | 弗吉尼亚暨州立大学知识产权公司 | 电穿孔系统 |
US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
JP6860497B2 (ja) * | 2015-03-31 | 2021-04-14 | オンコセック メディカル インコーポレイテッド | 改善された組織センシングに基づくエレクトロポレーションのためのシステム及び方法 |
EP3081198A1 (en) * | 2015-04-14 | 2016-10-19 | Eyevensys | Elektroporation device for the eye with a support and with a needle electrode |
CN106198990A (zh) * | 2015-04-30 | 2016-12-07 | 上海交通大学 | 一种对组织样本进行免疫标记的方法 |
EP4001456A1 (en) | 2015-08-18 | 2022-05-25 | SiO2 Medical Products, Inc. | Pharmaceutical and other packaging with low oxygen transmission rate |
KR101788301B1 (ko) * | 2015-09-17 | 2017-10-20 | 주식회사 엘림텍 | 전기천공장치 및 그 제어방법 |
CN106388933B (zh) * | 2016-09-14 | 2017-10-10 | 上海睿刀医疗科技有限公司 | 用于不可逆电穿孔设备的电极 |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11071860B2 (en) | 2019-02-06 | 2021-07-27 | Oncosec Medical Incorporated | Systems and methods for detecting fault conditions in electroporation therapy |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
CN114828947A (zh) * | 2019-10-18 | 2022-07-29 | 新南创新私人有限公司 | 电转移治疗递送装置、系统和方法 |
KR102290081B1 (ko) * | 2019-11-29 | 2021-08-13 | 부산대학교 산학협력단 | 전기천공장치 |
WO2021262989A1 (en) * | 2020-06-24 | 2021-12-30 | Oncosec Medical Incorporated | Transformable needle for electroporation |
AU2021357076A1 (en) * | 2020-10-08 | 2023-06-08 | Becton, Dickinson And Company | Delivery device and coated needle or cannula |
KR102576604B1 (ko) * | 2021-02-16 | 2023-09-08 | 주식회사 밀알 | 의료용 정밀 약물주입 및 전기천공 융합 전극 |
AU2022339915A1 (en) * | 2021-08-30 | 2024-04-04 | Nanovis, LLC | Devices and methods for treating infected tissue |
KR102576111B1 (ko) * | 2021-10-18 | 2023-09-08 | 주식회사 밀알 | 미들커넥터를 포함하는 가역적 전기천공시스템 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04158870A (ja) * | 1990-10-23 | 1992-06-01 | Olympus Optical Co Ltd | 治療器具 |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US20020198512A1 (en) * | 2001-06-11 | 2002-12-26 | Endobionics, Inc. | Electroporation microneedle and methods for its use |
WO2003075978A2 (en) * | 2002-03-07 | 2003-09-18 | Merck & Co., Inc. | Clinical syringe with electrical stimulation aspects |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2525398A (en) * | 1948-02-02 | 1950-10-10 | Arthur L Collins | Hypodermic syringe holder and guide |
US3313293A (en) * | 1964-01-13 | 1967-04-11 | Hewlett Packard Co | Multi-electrode needle |
GB8618253D0 (en) * | 1986-07-25 | 1986-09-03 | Wallace Ltd H G | Intermittent administration of therapeutic substance |
US4733661A (en) * | 1987-04-27 | 1988-03-29 | Palestrant Aubrey M | Guidance device for C.T. guided drainage and biopsy procedures |
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
EP0398960B1 (en) * | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
ES2130177T3 (es) * | 1991-08-10 | 1999-07-01 | Medical Res Council | Tratamiento de poblaciones de celulas. |
US5328451A (en) * | 1991-08-15 | 1994-07-12 | Board Of Regents, The University Of Texas System | Iontophoretic device and method for killing bacteria and other microbes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
AU6260896A (en) * | 1995-06-06 | 1996-12-24 | Board Of Regents, The University Of Texas System | Electrode system in iontophoretic treatment devices |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6055453A (en) * | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
DE19740825A1 (de) * | 1997-09-17 | 1999-03-18 | Laser & Med Tech Gmbh | Vorrichtung zur Erzeugung röhrenförmiger Nekrosen- und von Druckamplituden in Muskelgewebe |
US6356783B1 (en) * | 1997-11-20 | 2002-03-12 | David R. Hubbard, Jr. | Multi-electrode and needle injection device for diagnosis and treatment of muscle injury and pain |
US6135990A (en) * | 1997-12-17 | 2000-10-24 | University Of South Florida | Electroporation device and method |
US6778853B1 (en) * | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
US6302903B1 (en) * | 1998-07-07 | 2001-10-16 | Medtronic, Inc. | Straight needle apparatus for creating a virtual electrode used for the ablation of tissue |
EP2428249B1 (en) * | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6192270B1 (en) * | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
CN1191872C (zh) * | 1999-01-28 | 2005-03-09 | 塞托·帕尔斯科技公司 | 运送大分子进入细胞的装置 |
CA2394020C (en) | 1999-12-15 | 2011-04-05 | University Of South Florida | Electroporation device and method |
US6591133B1 (en) * | 2000-11-27 | 2003-07-08 | Microlin Llc | Apparatus and methods for fluid delivery using electroactive needles and implantable electrochemical delivery devices |
DE60238178D1 (de) * | 2001-01-16 | 2010-12-16 | Cytyc Surgical Products Palo A | Vorrichtung und verfahren zur behandlung des venösen reflux |
US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
US7141425B2 (en) * | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
CA2482183A1 (en) * | 2002-04-16 | 2003-10-30 | Cyto Pulse Sciences, Inc. | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
SE0201977D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
US7328064B2 (en) * | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20050070841A1 (en) * | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
JP4225743B2 (ja) | 2002-07-04 | 2009-02-18 | 株式会社東芝 | 無線端末及び通信制御方法 |
KR20050098277A (ko) | 2003-01-29 | 2005-10-11 | 이-필 파마 리미티드 | 위장관 내 약물의 능동 송달 |
CN1897920A (zh) * | 2003-10-31 | 2007-01-17 | 阿尔扎公司 | 用于经皮疫苗递送的系统和方法 |
US20050209548A1 (en) * | 2004-03-19 | 2005-09-22 | Dev Sukhendu B | Electroporation-mediated intravascular delivery |
US20070083239A1 (en) * | 2005-09-23 | 2007-04-12 | Denise Demarais | Methods and apparatus for inducing, monitoring and controlling renal neuromodulation |
US7776373B2 (en) * | 2004-11-19 | 2010-08-17 | Eteka Llc | Apparatus and method for the enhancement of food properties and food prepared therefrom |
US20060293725A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating fatty tissue sites using electroporation |
US8262885B2 (en) * | 2005-11-18 | 2012-09-11 | President And Fellows Of Harvard College | Dielectrophoretic tweezers apparatus and methods |
US20080045880A1 (en) | 2006-02-11 | 2008-02-21 | Rune Kjeken | Device and method for single-needle in vivo electroporation |
-
2007
- 2007-02-09 CA CA3063263A patent/CA3063263C/en active Active
- 2007-02-09 EA EA200870252A patent/EA200870252A1/ru unknown
- 2007-02-09 WO PCT/US2007/003615 patent/WO2007095140A2/en active Application Filing
- 2007-02-09 AU AU2007215263A patent/AU2007215263B2/en active Active
- 2007-02-09 US US11/704,591 patent/US10369359B2/en active Active
- 2007-02-09 CA CA2635437A patent/CA2635437C/en active Active
- 2007-02-09 KR KR1020087019463A patent/KR101385865B1/ko active IP Right Grant
- 2007-02-09 JP JP2008554405A patent/JP5059786B2/ja active Active
- 2007-02-09 CN CN2007800023139A patent/CN101370553B/zh active Active
- 2007-02-09 EP EP07750450.4A patent/EP1981581B1/en active Active
-
2008
- 2008-09-05 NO NO20083811A patent/NO340500B1/no unknown
-
2019
- 2019-07-09 US US16/506,888 patent/US11331479B2/en active Active
-
2022
- 2022-04-29 US US17/733,527 patent/US20230001190A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04158870A (ja) * | 1990-10-23 | 1992-06-01 | Olympus Optical Co Ltd | 治療器具 |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US20020198512A1 (en) * | 2001-06-11 | 2002-12-26 | Endobionics, Inc. | Electroporation microneedle and methods for its use |
WO2003075978A2 (en) * | 2002-03-07 | 2003-09-18 | Merck & Co., Inc. | Clinical syringe with electrical stimulation aspects |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018518314A (ja) * | 2015-06-25 | 2018-07-12 | ニューサウス・イノベーションズ・ピーティーワイ・リミテッド | 治療学的物質の局所的送達を制御する電気穿孔法システム |
JP2018198865A (ja) * | 2017-05-29 | 2018-12-20 | 株式会社ジェイメック | パルス電圧治療装置 |
Also Published As
Publication number | Publication date |
---|---|
CA2635437C (en) | 2020-01-28 |
NO20083811L (no) | 2008-09-05 |
US11331479B2 (en) | 2022-05-17 |
EP1981581B1 (en) | 2016-04-13 |
CA3063263A1 (en) | 2007-08-23 |
WO2007095140A2 (en) | 2007-08-23 |
US20200001076A1 (en) | 2020-01-02 |
EP1981581A2 (en) | 2008-10-22 |
US20070287950A1 (en) | 2007-12-13 |
AU2007215263B2 (en) | 2011-07-07 |
NO340500B1 (no) | 2017-05-02 |
CA3063263C (en) | 2024-01-16 |
WO2007095140A3 (en) | 2008-01-10 |
US20230001190A1 (en) | 2023-01-05 |
AU2007215263A1 (en) | 2007-08-23 |
US10369359B2 (en) | 2019-08-06 |
CN101370553A (zh) | 2009-02-18 |
CA2635437A1 (en) | 2007-08-23 |
JP5059786B2 (ja) | 2012-10-31 |
CN101370553B (zh) | 2013-04-10 |
KR20080110988A (ko) | 2008-12-22 |
KR101385865B1 (ko) | 2014-04-17 |
EP1981581A4 (en) | 2011-05-25 |
EA200870252A1 (ru) | 2009-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5059786B2 (ja) | 単針生体内エレクトロポレーションのための装置および方法 | |
US20080045880A1 (en) | Device and method for single-needle in vivo electroporation | |
JP4499295B2 (ja) | 細胞内への巨大分子の送達 | |
CA2337652C (en) | Skin and muscle-targeted gene therapy by pulsed electrical field | |
US6678556B1 (en) | Electrical field therapy with reduced histopathological change in muscle | |
US6713291B2 (en) | Electrodes coated with treating agent and uses thereof | |
AU2016282210B2 (en) | Electroporation system for controlled localized therapeutics delivery | |
JP2010506657A (ja) | 組織の不可逆的エレクトロポレーションに使用される、所定の導電率を有するゲル | |
EP2148721B1 (en) | Device and method for single-needle in vivo electroporation | |
KR102601524B1 (ko) | 미세전극을 사용한 조직 전기이동을 위한 소자 | |
JP2001506172A (ja) | 作用物質のイオン導入法による送達のための針 | |
US7713740B2 (en) | Method of using electric fields to facilitate the entry of molecules into cells in vivo | |
MX2008008981A (es) | Dispositivo y metodo para electropermeacion in vivo de una sola aguja | |
US7879610B1 (en) | Electroporation system and method for facilitating entry of molecules into cells in vivo | |
WO2023224829A1 (en) | Intracellular treatment device and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120416 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120511 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120703 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120802 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150810 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5059786 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |